Latest News: Proscia Receives FDA 510(k) Clearance For Concentriq AP-DxREAD THE PRESS RELEASE

HNL Lab Medicine to Go 100% Digital

Proscia
By Author Proscia | August 31, 2023

Laboratory Economics spoke with Jordan Olson, MD, Chair of the Department of Pathology at LVHN and Medical Director at Proscia customer HNL Lab Medicine. In this Q&A, Dr. Olson explains why now is the time for HNL to go digital and how his team will use our Concentriq Dx* enterprise pathology platform.

*Concentriq Dx is CE-marked under IVDR and is available for primary diagnosis in the US under the COVID-19 enforcement policy for remote pathology devices.

Our website uses cookies. By using this site, you agree to its use of cookies.